期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Effect of urate-lowering therapy with febuxostat on oxidative stress in hyperuricemic patients with chronic kidney disease stages 3-5
1
作者 ZHANG Xiaoxiao 《China Medical Abstracts(Internal Medicine)》 2019年第4期225-226,共2页
Objective To estimate the effect of urate-lowering therapy with febuxostat on oxidative stress in chronic kidney disease(CKD)stages 3-5 patients with hyperuricemia(HUA).Methods The study was a prospective cohort study... Objective To estimate the effect of urate-lowering therapy with febuxostat on oxidative stress in chronic kidney disease(CKD)stages 3-5 patients with hyperuricemia(HUA).Methods The study was a prospective cohort study.The patients of CKD stages 3-5 with HUA between June 2015 and June 2018 in the Affiliated Hospital of Qingdao University were prospectively analyzed.The patients were assigned to febuxostat(A)group,allopurinol(B)group and non-hyperuricemia(C)group according to the level of serum uric acid and the choice of urate-lowering drugs.Serum uric acid,hypersensitive C-reactive protein(hs-CRP),plasma malondialdehyde(MDA),superoxide dismutase(SOD)and endothelin-1(ET-1)were measured at baseline,1 month and 3 months after treatment and the changes of the values of inflammation and oxidative stress before or after treatment were compared. 展开更多
关键词 EFFECT urate-lowering disease
原文传递
A Systematic Review of Uric Acid Transporter 1(URAT1) Inhibitors for the Treatment of Hyperuricemia and Gout and an Insight into the Structure-activity Relationship(SAR) 被引量:1
2
作者 蔡文卿 刘巍 +2 位作者 刘长鹰 王建武 赵桂龙 《Chinese Journal of Structural Chemistry》 SCIE CAS CSCD 2017年第6期897-910,共14页
Gout is caused by the deposition of uric acid as monosodium urate(MSU). Chronic hyperuricemia is the necessary condition for MSU deposition, which arises from over-production and/or under-excretion of uric acid. Ren... Gout is caused by the deposition of uric acid as monosodium urate(MSU). Chronic hyperuricemia is the necessary condition for MSU deposition, which arises from over-production and/or under-excretion of uric acid. Renal under-excretion of uric acid accounts for greater than 90% of the patients with hyperuricemia, making URAT1 inhibitors, which act through uricosuric effect a promising class of urate-lowering therapy(ULT). This review aims at the summary and discussion of the latest development of URAT1 inhibitors for the treatment of hyperuricemia and gout and providing an insight into their structure-activity relationship(SAR), which will be helpful to the design of URAT1 inhibitors for both academic research and pharmaceutical industry. The current development pipeline of URAT1 inhibitors is promising and encouraging. 展开更多
关键词 GOUT HYPERURICEMIA urate-lowering therapy uricosuric URAT1 inhibitor structure-activity relationship (SAR)
下载PDF
Rapidly separating dissolving microneedles with sustained-release colchicine and stabilized uricase for simplified long-term gout management 被引量:1
3
作者 Yao Yang Zimu Li +10 位作者 Ping Huang Jiachan Lin Jinyuan Li Kexin Shi Jiahui Lin Jingwen Hu Zhuoxian Zhao Yongkang Yu Hongzhong Chen Xiaowei Zeng Lin Mei 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2023年第8期3454-3470,共17页
Despite growing prevalence and incidence,the management of gout remains suboptimal.The intermittent nature of the gout makes the long-term urate-lowering therapy(ULT)particularly important for gout management.However,... Despite growing prevalence and incidence,the management of gout remains suboptimal.The intermittent nature of the gout makes the long-term urate-lowering therapy(ULT)particularly important for gout management.However,patients are reluctant to take medication day after day to manage incurable occasional gout flares,and suffer from possible long-term toxicity.Therefore,a safe and easy-tooperate drug delivery system with simple preparation for the long-term management of gout is very necessary.Here,a chitosan-containing sustained-release microneedle system co-loaded with colchicine and uricase liposomes were fabricated to achieve this goal.This microneedle system was confirmed to successfully deliver the drug to the skin and maintain a one-week drug retention.Furthermore,its powerful therapeutic potency to manage gout was investigated in both acute gouty and chronic gouty models.Besides,the drug co-delivery system could help avoid long-term daily oral colchicine,a drug with a narrow therapeutic index.This system also avoids mass injection of uricase by improving its stability,enhancing the clinical application value of uricase.In general,this two-drug system reduces the dosage of uricase and colchicine and improves the patient’s compliance,which has a strong clinical translation. 展开更多
关键词 MICRONEEDLES COLCHICINE SUSTAINED-RELEASE URICASE Liposome Transdermal administration Gout management Long-term urate-lowering therapy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部